{"id":2546,"date":"2018-02-14T11:39:09","date_gmt":"2018-02-14T06:09:09","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2546"},"modified":"2023-04-04T10:49:33","modified_gmt":"2023-04-04T05:19:33","slug":"business-cocktail-latest-pharma-news","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news","title":{"rendered":"Business Cocktail"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Roivant expanding its horizon into metabolic diseases segment with USD 650 million diabetes pact with Poxel<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Roivant Sciences<\/strong> has&nbsp;recently signed&nbsp;a <strong>USD 650 million<\/strong> deal to acquire near-global rights to <strong>Poxel pharma\u2019s<\/strong> phase 3-ready Type 2 diabetes drug (<strong>imeglimin<\/strong>). It\u2019s been a while since Poxel was waiting for a partner capable of sharing the burden of a late-phase diabetes program. Now with the successful partnership deal, poxel can concentrate on further development of the respective drug without any financial hurdle.<\/p>\n<p style=\"text-align: justify;\"><strong>PolyPid listed for another IPO shot, seeking USD 86 million as it prepares for phase 3 trails<\/strong><\/p>\n<p style=\"text-align: justify;\">Israeli biotech <strong>PolyPid<\/strong> is moving forward and has listed itself on the <strong>Nasdaq<\/strong>, three years after the last misfire. The company is seeking a funding of <strong>USD 86 million<\/strong> to fuel its pipeline of locally-acting anti-infectives. The clinical-stage company officially filed the IPO documentation with the SEC filing recently.<\/p>\n<p style=\"text-align: justify;\"><strong>Pieris and Seattle Genetics recently signed a USD 1.2 billion biobucks pact for next-gen cancer drugs<\/strong><\/p>\n<p style=\"text-align: justify;\">Both Seattle Genetics and Pieris&nbsp;have recently signed a <strong>biobucks pact<\/strong> worth <strong>USD 1.2 billion<\/strong>, the pact is made to develop immuno-oncology therapies with expected promising outcomes. The upfront cost of the deal is just <strong>USD 30 million<\/strong> but will eventually swell upto <strong>USD 1.2 billion<\/strong> with the achievement of desired milestones.<\/p>\n<p style=\"text-align: justify;\"><strong>CRISPR Therapeutics CSO departs as Celgene sold another chunk of the shares<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CRISPR Therapeutics<\/strong> CSO <strong>Bill Lundberg<\/strong> has departed from the company breaking the news on the same day Celgene revealed that it has sold another chunk of its stakes in <strong>CRISPR\/Cas9 gene<\/strong> editing startup. Lundberg was leading the CRISPR Therapeutics R&amp;D operations since 2015.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roivant expanding its horizon into metabolic diseases segment with USD 650 million diabetes pact with Poxel Roivant Sciences has&nbsp;recently signed&nbsp;a USD 650 million deal to acquire near-global rights to Poxel pharma\u2019s phase 3-ready Type 2 diabetes drug (imeglimin). It\u2019s been a while since Poxel was waiting for a partner capable of sharing the burden of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1392,1388,1118,155,1390,1391,204,1385,1728,381,1387,420,1230,1261,639,1389,1386,1384,1383,534],"industry":[17225],"therapeutic_areas":[17235,17240,17231],"class_list":["post-2546","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bill-lundberg","tag-biobucks","tag-business-research","tag-celgene","tag-crispr-therapeutics","tag-crisprcas9-gene","tag-delveinsight","tag-imeglimin","tag-ipo","tag-market-research","tag-nasdaq","tag-news","tag-pharma-consultancy","tag-pharma-consulting","tag-pharma-news","tag-pieris","tag-polypid","tag-poxel","tag-roivant","tag-seattle-genetics","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Roivant Sciences, PolyPid, Pieris and Seattle Genetics - Buisness Coctail<\/title>\n<meta name=\"description\" content=\"Roivant Sciences has\u00a0recently signed\u00a0a USD 650 million deal to acquire near-global rights to Poxel pharma\u2019s phase 3-ready Type 2 diabetes drug (imeglimin).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roivant Sciences, PolyPid, Pieris and Seattle Genetics - Buisness Coctail\" \/>\n<meta property=\"og:description\" content=\"Roivant Sciences has\u00a0recently signed\u00a0a USD 650 million deal to acquire near-global rights to Poxel pharma\u2019s phase 3-ready Type 2 diabetes drug (imeglimin).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-14T06:09:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-04T05:19:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2450\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roivant Sciences, PolyPid, Pieris and Seattle Genetics - Buisness Coctail","description":"Roivant Sciences has\u00a0recently signed\u00a0a USD 650 million deal to acquire near-global rights to Poxel pharma\u2019s phase 3-ready Type 2 diabetes drug (imeglimin).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news","og_locale":"en_US","og_type":"article","og_title":"Roivant Sciences, PolyPid, Pieris and Seattle Genetics - Buisness Coctail","og_description":"Roivant Sciences has\u00a0recently signed\u00a0a USD 650 million deal to acquire near-global rights to Poxel pharma\u2019s phase 3-ready Type 2 diabetes drug (imeglimin).","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-02-14T06:09:09+00:00","article_modified_time":"2023-04-04T05:19:33+00:00","og_image":[{"width":2450,"height":1080,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news","name":"Roivant Sciences, PolyPid, Pieris and Seattle Genetics - Buisness Coctail","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","datePublished":"2018-02-14T06:09:09+00:00","dateModified":"2023-04-04T05:19:33+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Roivant Sciences has\u00a0recently signed\u00a0a USD 650 million deal to acquire near-global rights to Poxel pharma\u2019s phase 3-ready Type 2 diabetes drug (imeglimin).","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","width":2450,"height":1080,"caption":"News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop-300x132.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bill Lundberg<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">biobucks<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR\/Cas9 gene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">imeglimin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IPO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nasdaq<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pieris<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PolyPid<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Poxel<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roivant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Seattle Genetics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bill Lundberg<\/span>","<span class=\"advgb-post-tax-term\">biobucks<\/span>","<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">CRISPR Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">CRISPR\/Cas9 gene<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">imeglimin<\/span>","<span class=\"advgb-post-tax-term\">IPO<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">Nasdaq<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Pieris<\/span>","<span class=\"advgb-post-tax-term\">PolyPid<\/span>","<span class=\"advgb-post-tax-term\">Poxel<\/span>","<span class=\"advgb-post-tax-term\">Roivant<\/span>","<span class=\"advgb-post-tax-term\">Seattle Genetics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Feb 14, 2018","modified":"Updated on Apr 4, 2023"},"absolute_dates_time":{"created":"Posted on Feb 14, 2018 11:39 am","modified":"Updated on Apr 4, 2023 10:49 am"},"featured_img_caption":"News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2546"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2546\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2434"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2546"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2546"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}